Home › Companies › Pliant Therapeutics, Inc. › 2025-2026
At Pliant Therapeutics, Inc.'s shareholder meeting held June 11, 2026, in the 2025-2026 proxy season, 83 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 267 separate fund positions. On the most widely held item on that ballot — TO APPROVE, BY NON-BINDING ADVISORY VOTE, THE RESOLUTION APPROVING NAMED EXECUTIVE OFFICER… — Pliant Therapeutics, Inc.'s filing reports the proposal as approved, with 51.2% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Pliant Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 11, 2026.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Pliant Therapeutics, Inc.’s Form 8-K, filed June 11, 2026 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of June 11, 2026: 5 items on Pliant Therapeutics, Inc.’s Form 8-K, filed June 11, 2026: 2 approved · 3 without a stated outcome.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore Pliant Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Pliant Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 11, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Bernard Coulie, M.D., Ph.D., MBA | 18,824,540 | -- | -- | 11,807,308 | -- | 61% | Not verified | — |
| Elect Director: Gayle Crowell | 18,186,914 | -- | -- | 12,444,934 | -- | 59% | Not verified | — |
| Elect Director: Steve Krognes, MBA | 19,299,728 | -- | -- | 11,332,120 | -- | 63% | Not verified | — |
| 2. On a non-binding advisory basis, the compensation of the Company's named executive officers | 15,282,788 | 14,572,455 | 776,605 | -- | -- | 51.2% | Approved | — |
| 3. The selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 | 41,710,604 | 747,140 | 69,239 | -- | -- | 98% | Approved | — |
Source: Pliant Therapeutics, Inc., Form 8-K, filed with the SEC on June 11, 2026 — read the filing on EDGAR.
Each item below shows how the 83 asset managers that disclosed a Pliant Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
61% Majority: yes · of votes cast
Description as filed by funds: To elect three class III directors named in the proxy statement to our Board of Directors: Bernard Coulie, M.D., Ph.D., M.B.A.
Pliant Therapeutics, Inc.’s own tally for this item (“Elect Director: Bernard Coulie, M.D., Ph.D., MBA”): 18,824,540 for, 11,807,308 withheld, per its Form 8-K filed June 11, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 61% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 17 asset managers below reported 2,831,774 for, 1,004,342 withheld, 49 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,455,855 | 0 | 49 | 4,684 | For |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 553,630 | Withhold |
| Fidelity | 0 | 0 | 0 | 322,903 | Withhold |
| BlackRock | 153,340 | 0 | 0 | 0 | For |
| Invesco | 85,478 | 0 | 0 | 0 | For |
| Goldman Sachs | 64,719 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 55,129 | 0 | 0 | 0 | For |
| Nationwide | 0 | 0 | 0 | 50,300 | Withhold |
| GuideStone | 0 | 0 | 0 | 37,153 | Withhold |
| Blackstone Alternative Investment Funds | 0 | 0 | 0 | 13,600 | Withhold |
| Equitable | 11,562 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 0 | 9,535 | Withhold |
| Prudential/PGIM | 0 | 0 | 0 | 7,400 | Withhold |
| Northern Trust | 5,691 | 0 | 0 | 0 | For |
| Lincoln Financial | 0 | 0 | 0 | 2,509 | Withhold |
| Allianz | 0 | 0 | 0 | 2,307 | Withhold |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 321 | Withhold |
Combines 3 wordings of this item as funds reported it.
59% Majority: yes · of votes cast
Description as filed by funds: To elect three class III directors named in the proxy statement to our Board of Directors: Gayle Crowell
Pliant Therapeutics, Inc.’s own tally for this item (“Elect Director: Gayle Crowell”): 18,186,914 for, 12,444,934 withheld, per its Form 8-K filed June 11, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 59% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 17 asset managers below reported 2,620,756 for, 1,215,359 withheld, 50 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,455,854 | 0 | 50 | 4,684 | For |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 553,630 | Withhold |
| Fidelity | 0 | 0 | 0 | 322,903 | Withhold |
| BlackRock | 153,340 | 0 | 0 | 0 | For |
| Invesco | 0 | 0 | 0 | 85,478 | Withhold |
| Goldman Sachs | 0 | 0 | 0 | 64,719 | Withhold |
| Columbia Threadneedle | 0 | 0 | 0 | 55,129 | Withhold |
| Nationwide | 0 | 0 | 0 | 50,300 | Withhold |
| GuideStone | 0 | 0 | 0 | 37,153 | Withhold |
| Blackstone Alternative Investment Funds | 0 | 0 | 0 | 13,600 | Withhold |
| Equitable | 11,562 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 0 | 9,535 | Withhold |
| Prudential/PGIM | 0 | 0 | 0 | 7,400 | Withhold |
| Northern Trust | 0 | 0 | 0 | 5,691 | Withhold |
| Lincoln Financial | 0 | 0 | 0 | 2,509 | Withhold |
| Allianz | 0 | 0 | 0 | 2,307 | Withhold |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 321 | Withhold |
Combines 3 wordings of this item as funds reported it.
63% Majority: yes · of votes cast
Description as filed by funds: To elect three class III directors named in the proxy statement to our Board of Directors: Steve Krognes, M.B.A.
Pliant Therapeutics, Inc.’s own tally for this item (“Elect Director: Steve Krognes, MBA”): 19,299,728 for, 11,332,120 withheld, per its Form 8-K filed June 11, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 63% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 17 asset managers below reported 3,159,685 for, 676,434 withheld, 46 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,460,542 | 0 | 46 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 553,630 | Withhold |
| Fidelity | 322,903 | 0 | 0 | 0 | For |
| BlackRock | 153,340 | 0 | 0 | 0 | For |
| Invesco | 85,478 | 0 | 0 | 0 | For |
| Goldman Sachs | 64,719 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 55,129 | 0 | 0 | 0 | For |
| Nationwide | 0 | 0 | 0 | 50,300 | Withhold |
| GuideStone | 0 | 0 | 0 | 37,153 | Withhold |
| Blackstone Alternative Investment Funds | 0 | 0 | 0 | 13,600 | Withhold |
| Equitable | 11,562 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 0 | 9,535 | Withhold |
| Prudential/PGIM | 0 | 0 | 0 | 7,400 | Withhold |
| Northern Trust | 5,691 | 0 | 0 | 0 | For |
| Lincoln Financial | 0 | 0 | 0 | 2,509 | Withhold |
| Allianz | 0 | 0 | 0 | 2,307 | Withhold |
| Advisors' Inner Circle Fund III | 321 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
51.2% Approved · of votes cast
Description as filed by funds: TO APPROVE, BY NON-BINDING ADVISORY VOTE, THE RESOLUTION APPROVING NAMED EXECUTIVE OFFICER COMPENSATION.
Pliant Therapeutics, Inc.’s own tally for this item (“2. On a non-binding advisory basis, the compensation of the Company's named executive officers”): 15,282,788 for, 14,572,455 against — passed, per its Form 8-K filed June 11, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal No. 2: The Company's stockholders approved, on a non-binding advisory basis, the compensation of the Company's named executive officers.”
Support: 51.2% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,306,907 | 153,678 | 3 | 0 | Mixed |
| BRIDGEWAY FUNDS INC | 0 | 553,630 | 0 | 0 | Against |
| Fidelity | 0 | 322,903 | 0 | 0 | Against |
| BlackRock | 153,340 | 0 | 0 | 0 | For |
| Invesco | 0 | 85,478 | 0 | 0 | Against |
| Goldman Sachs | 0 | 64,719 | 0 | 0 | Against |
| Columbia Threadneedle | 0 | 55,129 | 0 | 0 | Against |
| Nationwide | 0 | 50,300 | 0 | 0 | Against |
| GuideStone | 0 | 37,153 | 0 | 0 | Against |
| Blackstone Alternative Investment Funds | 0 | 13,600 | 0 | 0 | Against |
| Equitable | 11,562 | 0 | 0 | 0 | For |
| Jackson National | 0 | 9,535 | 0 | 0 | Against |
| Prudential/PGIM | 0 | 7,400 | 0 | 0 | Against |
| Northern Trust | 5,691 | 0 | 0 | 0 | For |
| Lincoln Financial | 0 | 2,509 | 0 | 0 | Against |
| Allianz | 0 | 2,307 | 0 | 0 | Against |
| Advisors' Inner Circle Fund III | 321 | 0 | 0 | 0 | For |
Fund voting reports, all 17 managers: 2,477,821 for, 1,358,341 against, 3 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Blue Owl Capital Holdings LP | 2,969,199 | 0 | 0 | 0 | For |
| ADAR1 Capital Management, LLC | 0 | 2,584,468 | 0 | 0 | Against |
| ACADIAN ASSET MANAGEMENT LLC | 0 | 2,074,315 | 0 | 0 | Against |
| Citadel | 1,793,410 | 0 | 0 | 0 | For |
| Two Sigma | 0 | 1,714,620 | 0 | 0 | Against |
| Woodline Partners LP | 1,410,513 | 0 | 0 | 0 | For |
| Peapod Lane Capital LLC | 0 | 843,890 | 0 | 0 | Against |
| Redmile Group, LLC | 0 | 772,126 | 0 | 0 | Against |
| BlackRock | 768,880 | 1,193 | 0 | 0 | For |
| Eversept Partners, LP | 0 | 0 | 754,014 | 0 | Abstain |
| MARSHALL WACE, LLP | 0 | 651,963 | 0 | 0 | Against |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0 | 553,630 | 0 | 0 | Against |
| Bessemer Trust CO of Delaware, N.A. | 0 | 536,849 | 0 | 0 | Against |
| BESSEMER TRUST CO | 0 | 532,079 | 0 | 0 | Against |
| BESSEMER TRUST Co OF FLORIDA | 0 | 532,079 | 0 | 0 | Against |
| Bessemer Trust Co of California, N.A. | 0 | 532,079 | 0 | 0 | Against |
| Bessemer Trust Co of Nevada, National Association | 0 | 532,079 | 0 | 0 | Against |
| Prosight Management, LP | 531,156 | 0 | 0 | 0 | For |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 0 | 507,917 | 0 | 0 | Against |
| DAFNA Capital Management LLC | 487,000 | 0 | 0 | 0 | For |
| Connor, Clark & Lunn Investment Management Ltd. | 0 | 442,039 | 0 | 0 | Against |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 438,347 | 0 | 0 | Against |
| Laurion Capital Management LP | 0 | 412,796 | 0 | 0 | Against |
| Renaissance | 0 | 383,527 | 0 | 0 | Against |
| Vanguard | 359,047 | 7,850 | 0 | 0 | For |
Institutional-manager reports, all 72 managers: 8,954,924 for, 15,275,674 against, 754,014 abstained, 4,500 not voted. Showing the 25 largest; every one is in the interactive database (link above).
98% Approved · of votes cast
Description as filed by funds: TO RATIFY THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.
Pliant Therapeutics, Inc.’s own tally for this item (“3. The selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026”): 41,710,604 for, 747,140 against — passed, per its Form 8-K filed June 11, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal No. 3: The Company's stockholders ratified the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 17 asset managers below reported 3,836,165 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,460,588 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 553,630 | 0 | 0 | 0 | For |
| Fidelity | 322,903 | 0 | 0 | 0 | For |
| BlackRock | 153,340 | 0 | 0 | 0 | For |
| Invesco | 85,478 | 0 | 0 | 0 | For |
| Goldman Sachs | 64,719 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 55,129 | 0 | 0 | 0 | For |
| Nationwide | 50,300 | 0 | 0 | 0 | For |
| GuideStone | 37,153 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 13,600 | 0 | 0 | 0 | For |
| Equitable | 11,562 | 0 | 0 | 0 | For |
| Jackson National | 9,535 | 0 | 0 | 0 | For |
| Prudential/PGIM | 7,400 | 0 | 0 | 0 | For |
| Northern Trust | 5,691 | 0 | 0 | 0 | For |
| Lincoln Financial | 2,509 | 0 | 0 | 0 | For |
| Allianz | 2,307 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 321 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 61,920,249 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 3.97% |
| 2 | BRIDGEWAY FUNDS INC | 0.89% |
| 3 | Fidelity | 0.52% |
| 4 | BlackRock | 0.25% |
| 5 | Invesco | 0.14% |
| 6 | Goldman Sachs | 0.10% |
| 7 | Columbia Threadneedle | 0.09% |
| 8 | Nationwide | 0.08% |
| 9 | GuideStone | 0.06% |
| 10 | Blackstone Alternative Investment Funds | 0.02% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Blue Owl Capital Holdings LP | 4.80% |
| 2 | ADAR1 Capital Management, LLC | 4.17% |
| 3 | ACADIAN ASSET MANAGEMENT LLC | 3.35% |
| 4 | Citadel | 2.90% |
| 5 | Two Sigma | 2.77% |
| 6 | Woodline Partners LP | 2.28% |
| 7 | Peapod Lane Capital LLC | 1.36% |
| 8 | Redmile Group, LLC | 1.25% |
| 9 | BlackRock | 1.24% |
| 10 | Eversept Partners, LP | 1.22% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Tang Capital Management LLC | 9.46% | DEF14A |
| ADAR1 Capital Management, LLC | 8.90% | 13G |
| Citadel Advisors | 5.27% | 13F |
| Vanguard Group | 4.55% | 13F |
| Bernard Coulie, M.D., Ph.D., M.B.A. | 4.05% | DEF14A |
| Two Sigma | 3.64% | 13F |
| Kenneth Griffin | 3.46% | 13G |
| Woodline Partners LP | 3.27% | 13G |
| Renaissance Technologies | 2.99% | 13F |
| Millennium Management | 1.91% | 13F |
Percentages above are of 61,920,249 shares outstanding, as reported by Pliant Therapeutics, Inc. on its Form 10-Q dated May 8, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Pliant Therapeutics, Inc.’s 10-Q dated May 8, 2026. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
Pliant Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
proxyvotesnow.com, “Pliant Therapeutics (PLRX) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/pliant-therapeutics-inc/2026 (version of November 8, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.